Ocular Therapeutix (OCUL)

The company’s commercial product, Dextenza, is an intracanalicular insert that delivers dexamethasone to treat ocular inflammation and pain following ophthalmic surgery and is also used for ocular itching associated with allergic conjunctivitis. The insert is placed in the tear duct, where it provides sustained corticosteroid delivery and then resorbs, distinguishing it from conventional topical steroid regimens.

Ocular Therapeutix also develops a pipeline of sustained-release candidates for retinal and glaucoma-related conditions. Programs have included OTX-TKI, an axitinib-based intravitreal implant candidate for wet age-related macular degeneration and other retinal vascular diseases, as well as OTX-TIC for glaucoma and ocular hypertension. These assets reflect the company’s broader effort to apply long-acting delivery to chronic eye disorders that typically require ongoing treatment.

As a listed biotech company, Ocular Therapeutix combines an approved ophthalmic product with higher-risk development programs. Its investment profile depends on commercial execution for Dextenza, clinical data from pipeline candidates, regulatory progress, manufacturing reliability, and competition from established eye-care companies developing alternative sustained-release or biologic treatments.